What is Brightgene Bio-medical Technology Co Cash Flow from Financing?
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2025,
Brightgene Bio-medical Technology Co paid¥0 Mil more to buy back shares than it received from issuing new shares.
It spent¥4 Mil paying down its debt.
It paid¥0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spent¥20 Mil paying cash dividends to shareholders.
It received¥193 Mil on other financial activities.
In all, Brightgene Bio-medical Technology Coearned¥169 Mil on financial activities for the
three
months ended in Mar. 2025.
Brightgene Bio-medical Technology Co Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Brightgene Bio-medical Technology Co Cash Flow from Financing Chart
Brightgene Bio-medical Technology Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥156 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co (SHSE:688166) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Brightgene Bio-medical Technology Co's issuance of stock for the
three
months ended in Mar. 2025 was ¥0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Brightgene Bio-medical Technology Co's repurchase of stock for the
three
months ended in Mar. 2025 was ¥0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Brightgene Bio-medical Technology Co's net issuance of debt for the
three
months ended in Mar. 2025 was ¥-4 Mil.
Brightgene Bio-medical Technology Co spent¥4 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Brightgene Bio-medical Technology Co's net issuance of preferred for the
three
months ended in Mar. 2025 was ¥0 Mil.
Brightgene Bio-medical Technology Co paid¥0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Brightgene Bio-medical Technology Co's cash flow for dividends for the
three
months ended in Mar. 2025 was ¥-20 Mil.
Brightgene Bio-medical Technology Co spent¥20 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Brightgene Bio-medical Technology Co's other financing for the
three
months ended in Mar. 2025 was ¥193 Mil.
Brightgene Bio-medical Technology Co received¥193 Mil on other financial activities.
Brightgene Bio-medical Technology Co Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Brightgene Bio-medical Technology Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Brightgene Bio-medical Technology Co Business Description
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:688166 has been successfully added to your 